Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06195319 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
A Phase 1 study of Metabolism and Absorption, sponsored by Cassava Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06195319: Completed Phase 1 study of Metabolism and Absorption, sponsored by Cassava Sciences.
NCT06195319 is a Phase 1 study of Metabolism and Absorption that has completed, run by Cassava Sciences. The registered enrollment target is 8 participants, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06195319, a Phase 1 study of Metabolism and Absorption, has completed, sponsored by Cassava Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the absorption, metabolism, and excretion of \[14C\]-simufilam in healthy male subjects following a single oral administration of 100 mg of (approximately 100 µCi) \[14C\]-simufilam.
Primary Outcome
Area Under the Curve for each total radioactivity, parent drug and metabolite(s) in plasma.
Conditions Studied
Interventions
- DRUG Simufilam
Study Locations (1)
Wisconsin
- Fortrea - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 1 |
What the finished NCT06195319 record still lists
NCT06195319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Metabolism appearing as the primary indexed condition, and to 1 intervention - of which Simufilam is the first listed.
NCT06195319 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06195319 about?
NCT06195319 is a clinical study titled "Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects". To evaluate the absorption, metabolism, and excretion of \[14C\]-simufilam in healthy male subjects following a single oral administration of 100 mg of (approximately 100 µCi) \[14C\]-simufilam.
What is the current status of trial NCT06195319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-02-07. Estimated completion is 2024-03-27.
What conditions does trial NCT06195319 study?
This clinical trial studies the following conditions: Metabolism, Absorption, Excretion.
What interventions are being tested in trial NCT06195319?
The interventions under investigation include: Simufilam (DRUG).
Who is sponsoring clinical trial NCT06195319?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06195319 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06195319's enrollment target sits among peer trials
8 17th of 19 higher than 2 of 19 other Metabolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE
COMPLETED · Phase 1
-
Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females
COMPLETED · Phase 1
-
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
RECRUITING · NA
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants
RECRUITING
-
Caloric Balance Markers Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI